Results 101 to 110 of about 1,126 (138)

CO31 | Immune system profiling in FVIII-treated and emicizumab-treated pediatric HA patients

Bleeding, Thrombosis and Vascular Biology
Background: Prophylactic treatments to prevent bleeding are considered the standard therapy in Hemophilia A (HA) and inhibitor formation is the main complication of FVIII infusion.
doaj   +1 more source

Implementing an assay detecting anti-drug antibody against emicizumab: experience from one center in France

Background Emicizumab is an antibody that mimics the function of factor (F)VIII and has been approved for prophylaxis in hemophilia A patients. However, the development of anti-drug antibodies (ADA) against emicizumab, although rare, can impair its ...
Lenting, Peter J, Lasne, Dominique, Auditeau, Claire, Valsecchi, Carla, Bentounes, Nun Kalim, Harroche, Annie, Peyvandi, Flora, Bally, Cécile, Borgel, Delphine, Le-Goff, Amandine, Lenting, Peter   +10 more
core   +1 more source

PO123 | PERIOPERATIVE MANAGEMENT OF FEMORAL FRACTURE SURGERY IN AN ELDERLY PATIENT WITH ACQUIRED HEMOPHILIA A RECEIVING EMICIZUMAB

Bleeding, Thrombosis and Vascular Biology
Background. Acquired hemophilia A (AHA) is a rare autoimmune bleeding disorder predominantly affecting elderly patients, in whom major surgery represents a particularly high-risk clinical scenario.
Chiara Simion
doaj  

Emicizumab state-of-the-art update

Haemophilia, 2022
AbstractIntroductionEmicizumab is a bispecific monoclonal antibody developed to address the unmet needs of clotting factor replacement therapy and has become the benchmark for optimal prophylaxis in managing patients with haemophilia A with inhibitors.
Johnny Mahlangu, Alfonso Iorio, Gili Kenet   +2 more
exaly   +5 more sources

Functional determination of emicizumab in presence of factor VIII activity

Journal of Thrombosis and Haemostasis, 2023
Background: Accurate measurement of emicizumab in the presence of factor (F) VIII is required in patients with severe hemophilia A treated with emicizumab, as well as additional need for FVIII substitution or emicizumab prophylaxis in patients with ...
Claudia Klein
exaly   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Emicizumab

Reactions Weekly
Stephanie J. Phelps, Tracy M. Hagemann, Kelley R. Lee   +2 more
  +12 more sources

Emicizumab

Reactions Weekly, 2023
  +8 more sources

Emicizumab

Reactions Weekly, 2022
  +6 more sources

Emicizumab for the treatment of acquired hemophilia A

Blood, 2021
Abstract Acquired hemophilia A (AHA) is a severe bleeding disorder caused by inhibiting autoantibodies to coagulation factor VIII (FVIII). For hemostatic treatment, bypassing agents and human or porcine FVIII are currently standard of care.
Paul Knoebl, Johannes Thaler, Petra Jilma, Peter Quehenberger, Karoline Gleixner, Wolfgang R. Sperr   +5 more
openaire   +2 more sources

The role of emicizumab in acquired hemophilia A

Hematology, 2023
Abstract Acquired hemophilia is a rare bleeding disorder that predominantly affects older people with potential underlying comorbidities, including cardiovascular and thrombotic risk factors. The current standard therapies with hemostatic agents for acute bleeding and immunosuppression often require inpatient management, are not approved
Jacqueline, Poston, Rebecca, Kruse-Jarres   +1 more
openaire   +2 more sources